SCHEMBL19923199

SCHEMBL19923199

O=Cc1ccc(O)c(C(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.57
PTGS2 P35354 1/20 0.57
RAB9A P51151 1/20 0.57
ALDH1A1 P00352 6/20 0.47
ALDH5A1 P51649 3/20 0.47
ABAT P80404 3/20 0.47
TRIM24 O15164 1/20 0.47
HPGD P15428 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TRIM33 Q9UPN9 1/20 0.47
AOX1 Q06278 1/20 0.43
XDH P47989 1/20 0.37
TTR P02766 1/20 0.36
LCK P06239 1/20 0.35
DRD1 P21728 1/20 0.35
EGFR P00533 1/20 0.35
TSHR P16473 1/20 0.34
ERN1 O75460 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28050177 0.84 KDM4E (0.57) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL13257341 0.83 KDM4E (0.61) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL18714281 0.83 KDM4E (0.61) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL3429786 0.80 KDM4E (0.57) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL31256694 0.80 KDM4E (0.57) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL14456529 0.78 RAB9A (0.55) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL31136826 0.76 ALDH1A1 (0.45) KDM4EPTGS2RAB9AALDH1A1TDP1
SCHEMBL14396702 0.76 ALDH1A1 (0.38) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL7245766 0.76 ALDH1A1 (0.56) KDM4EPTGS2RAB9AALDH1A1ALDH5A1
SCHEMBL13787395 0.76 KDM4E (0.52) KDM4EPTGS2RAB9AALDH1A1ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018045142-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (JP) 2018-03-08 US disclosed
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS, INC. (JP) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065917-A1 IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF CD274, PDCD1, PDCD1LG2 KDM4E 1808/4885PTGS2 4671/4885RAB9A 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.